trimegestone

Small moleculeexperimental

Trimegestone, sold under the brand names Ondeva and Totelle among others, is a progestin medication which is used in menopausal hormone therapy and in the prevention of postmenopausal osteoporosis. It was also under development for use in birth control pills to prevent pregnancy, but ultimately was not marketed for this purpose. The medication is available alone or in combination with an estrogen. It is taken by mouth. — Wikipedia

Clinical trial activity

3 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
2

Earliest trial started Feb 1, 2005 (NCT00195455)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C[C@H](O)C(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@@]21C
Mol. weight
342.48 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 17-(2-hydroxy-1-oxopropyl)-17-methylestra-4,9-dien-3-one
  • 21-hydroxypromegestone
  • ru 27987
  • ru-27987
  • ru-27987
  • ru-27987
  • ru 27988
  • ru-27988
  • trimegeston
  • trimegestone
  • trimegestone
  • trimegestone
  • trimegestone
  • trimegestone
  • trimegestone
  • trimegestone
  • trimegestone
  • trimegestone, (17beta(r))-isomer

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03343912Phase 1Nov 10, 2017Galeno Desenvolvimento de Pesquisas, SocraTec R&D GmbH
NCT00472004Phase 4Feb 1, 2006Pfizer
NCT00195455Phase 4Feb 1, 2005Pfizer, Wyeth
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PfizerFor profit2212005
Galeno Desenvolvimento de PesquisasAcademic/Hospital1112017
SocraTec R&D GmbHFor profit1012017
WyethFor profit1012005
4 organizations
Page 1 / 1